Refractory Lung Small Cell Carcinoma clinical trials at UC Cancer
1 research study open to eligible people
ATR Kinase Inhibitor VX-970 and Irinotecan Hydrochloride combination for solid tumors that are metastatic or cannot be removed
“Experimental targeted cancer therapy and chemotherapy combination for tumors that have returned, spread, or cannot be removed”
open to eligible people ages 18 years and up
This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
at UC Davis UCSF